The total incident cases of BRAF Mutated Non-small Cell Lung Cancer (NSCLC) in the 7MM was 19,275 in 2017. BRAF Mutated NSCLC accounted for around 5% of the total cases of NSCLC. In 2017 with 8,979 cases the United states accounted for the highest number of cases of BRAF Mutated NSCLC while Japan with around 1,000 cases had the lowest number of cases among seven major markets.
The market size of BRAF Mutated Non-small Cell Lung Cancer in 7MM was found to be USD 273 Million in 2017, which is expected to increase during the forecast period 2017-2030.
Some of the key players in the BRAF Mutated NSCLC market include Roche, Pfizer, Novartis and many others.
For more details visit:
https://www.delveinsight.com/report-store/braf-mutated-non-small-cell-lung-cancer-market